Acute lymphoblastic leukemia and down syndrome: 6-mercaptopurine and methotrexate metabolites during maintenance therapy

Leukemia. 2021 Mar;35(3):863-866. doi: 10.1038/s41375-020-0946-2. Epub 2020 Jul 4.

Anna Østergaard^{1

2

3}, Cathrine Bohnstedt¹, Kathrine Grell^{1

4}, Matilda Degn¹, Bernward Zeller⁵, Mervi Taskinen⁶, Solveig Hafsteinsdottir⁷, Helga Björgvinsdóttir⁷, Mats Heyman⁸, Peter Hoogerbrugge^{2

3}, Kjeld Schmiegelow^{9

10}; Nordic Society of Paediatric Haematology and Oncology (NOPHO)

¹ Department of Pediatrics and Adolescent Medicine, The Juliane Marie Centre, The University Hospital Rigshospitalet, Copenhagen, Denmark.
² Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
³ Faculty of Medicine, Utrecht University, Utrecht, Netherlands.
⁴ Section of Biostatistics, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
⁵ Department of Paediatrics, University Hospital Oslo, Oslo, Norway.
⁶ New Children's Hospital, Helsinki University Hospital, Helsinki University, Helsinki, Finland.
⁷ Department of Paediatrics, University Hospital Reykjavik, Reykjavik, Iceland.
⁸ Childhood Cancer Research Unit Department of Women's and Children's Health, Karolinska Institute, Stockholm, Sweden.
⁹ Department of Pediatrics and Adolescent Medicine, The Juliane Marie Centre, The University Hospital Rigshospitalet, Copenhagen, Denmark. kjeld.schmiegelow@regionh.dk.
¹⁰ Institute of Clinical Medicine, The Faculty of Health Sciences, The University of Copenhagen, Copenhagen, Denmark. kjeld.schmiegelow@regionh.dk.

No abstract available

Publication types